AptarGroup (ATR) announced that Gael Touya, most recently Aptar Pharma president, has been appointed president and CEO, effective September 1. He will succeed Stephan Tanda, who has served as president and CEO since 2017. Stephan is expected to continue to work closely with Touya and the board as an advisor through the end of the year. Tanda intends to retire from Aptar’s board by the end of 2026 and the board will appoint Gael as a director on September 1.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATR:
- AptarGroup: Solid Strategic Position and Structural Growth Offset by Near-Term Earnings Headwinds, Warranting a Hold Rating
- AptarGroup Earnings Call Balances Growth With Margin Strain
- AptarGroup price target raised to $147 from $142 at BofA
- AptarGroup price target raised to $156 from $145 at Baird
- Balanced View on AptarGroup: Solid Underlying Pharma Performance Offset by Near-Term Headwinds and Underwhelming Beauty & Closures, Justifying a Hold Rating